{"id":"NCT00082628","sponsor":"EMD Serono","briefTitle":"Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients","officialTitle":"A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety and Efficacy of Serostim®, r-hGH in the Treatment and Maintenance of Human Immunodeficiency HIV-Associated Adipose Redistribution Syndrome, or HARS","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2004-05-28","primaryCompletion":"2005-09-28","completion":"2005-09-28","firstPosted":"2004-05-17","resultsPosted":"2018-07-20","lastUpdate":"2018-07-20"},"enrollment":326,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["HIV Infections","Lipodystrophy"],"interventions":[{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Serostim® 4 mg","otherNames":["recombinant human growth hormone (r-hGH)"]},{"type":"DRUG","name":"Serostim® 2 mg","otherNames":["recombinant human growth hormone (r-hGH)"]}],"arms":[{"label":"Period I: Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Period I: Serostim® 4 mg","type":"EXPERIMENTAL"},{"label":"Period II: Serostim® 4 mg to Placebo","type":"EXPERIMENTAL"},{"label":"Period II: Serostim® 4 mg to Serostim® 2 mg","type":"EXPERIMENTAL"},{"label":"Period II: Placebo to Placebo/Serostim® 4 mg","type":"EXPERIMENTAL"}],"summary":"The primary objective of the study is to determine if Serostim® 4 mg administered daily for 12 weeks as treatment for the abnormal fat accumulation and distribution associated with HIV-associated Adipose Redistribution Syndrome (HARS) reduces Visceral Adipose Tissue (VAT, measured by CT scan) more effectively than placebo.","primaryOutcome":{"measure":"Treatment Period I: Change From Baseline in Absolute Area of Visceral Adipose Tissue (VAT) at Week 12","timeFrame":"Baseline, Week 12","effectByArm":[{"arm":"Period I: Placebo","deltaMin":0.5,"sd":34.5},{"arm":"Period I: Serostim® 4 mg","deltaMin":-32.6,"sd":37.9}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":31,"countries":["United States","Canada"]},"refs":{"pmids":[],"seeAlso":["http://www.serostim.com","http://www.ncbi.nlm.nih.gov/pubmed/17592343?itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum&ordinalpos=1","http://journals.lww.com/jaids/Fulltext/2007/07010/Recombinant_Human_Growth_Hormone_to_Treat.6.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":81},"commonTop":["Oedema peripheral","Arthralgia","Pain in extremity","Headache","Blood glucose increased"]}}